Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

2902 - Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy


08 Sep 2017


Breast cancer, early stage


Breast Cancer;  Prostate Cancer


Konstantinos Tryfonidis


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


K. Tryfonidis1, C. Poncet1, L. Slaets1, G. Viale2, F. de Snoo3, K. Aalders1, L. Van'T Veer4, E. Rutgers5, M. Piccart6, J. Bogaerts1, F. Cardoso7

Author affiliations

  • 1 Eortc, European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 2 Pathology, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 3 Medical, Agendia N.V, 1098 XH - Amsterdam/NL
  • 4 University Of California, University of California San Francisco, 94143 - San Francisco/US
  • 5 Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 6 Medical Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 7 Breast Unit, Champalimaud Foundation Cancer Center, 1400-038 - Lisboa/PT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2902


Adjuvant systemic therapy for pT1abN0 breast cancer is controversial, as these tumors overall have a low relapse risk. The best tool to identify a subgroup that would benefit from adjuvant treatment is unknown.


This subgroup included patients with pT1abN0 tumors enrolled in MINDACT who had both their genomic risk G (per MammaPrint®) & clinical risk C (per a modified version Adjuvant! Online) assessed. Patients characterized as low-risk in both assessments were spared chemotherapy (CT), while in those characterized as C&G high CT was advised. Discordant cases were randomized to receive CT based on the C or the G result. Here, we report the 5-year rates of distant metastasis-free survival (DMFS), distant metastases-free interval (DMFI) & overall survival (OS) for pT1abN0 patients who received or not CT based on their G or C risk result.


826/6693 (12.3%) patients with pT1abN0 tumors were enrolled in MINDACT. 310/826 (37.5%) were ≥ 60 years & 525/826 (63.6%) postmenopausal. 727/826 samples were reviewed by central pathology; 585/727 (80.5%) were invasive ductal, 662/727 (91.1%) ER positive, 46/727 HER2 positive (6.3%) & 81/727 (11.1%) were grade 3 tumors. IHC subtype classification identified 426/727 (58.6%) as Luminal A; 193/727 (26.5%) Luminal B; 38/727 (5.2%) Luminal B/HER2 positive; 8/727 (1.1%) HER2- positive; 37/727 (5.1%) triple-negative tumors. Almost all patients (820/826; 99.3%) were clinical low-risk (CL). Overall, 624/826 (75.5%) were CL/GL & 196/826 (23.7%) were CL/GH (5 patients were CH/GL, no cases were CH/GH, 1 missing). 5-year DMFS for patients with CL/GH pT1abN0 tumors who received CT was 97.3% (95% CI, 89.4-99.3) vs 91.4% (95% CI, 82.6-95.9) for those who did not. 5-years DMFI & OS for these patients treated with CT were 98.8% (95% CI, 91.9-99.8) & 98.5% (95% CI, 89.6- 99.8) vs 91.4% (95% CI, 82.6- 95.9) & 95.8% (89.1- 98.4%) respectively for those who did not receive CT.


Biological characteristics can be used as determinants of adjuvant CT administration for T1abN0 tumors. An important portion (23.7%) of these small tumors was CL but GH (MammaPrint®) risk and derived a benefit from CT.

Clinical trial identification

The main MINDACT study: ClinicalTrials.gov number: NCT00433589, EudraCT number:2005-002625-31

Legal entity responsible for the study

European Organization for Research and Treatment of Cancer (EORTC)




L. Van \'t Veer: Personal fees and other support from Agendia NV outside the submitted work. Co- inventor on a patent related to MammaPrint: Diagnosis and prognosis of breast cancer patients (WO2002103320, licensed to Agendia, NV). M. Piccart: Consulting or advisory role for AstraZeneca, MSD, Novartis, Pfizer, Roche- Genentech, Periphagen, Huya, Debiopharm, PharmaMar, Radius. Research funding from most above mentioned companies. F. Cardoso: Consultancy/research grants from Astellas/Medivation, AstraZeneca, Celgene, Daiichi- Sankyo, Eisai, GE Oncology, Genentech, Glaxo Smith Kline (GSK), Macrogenics, Merck- Sharp, Merus BV, Novartis, Pfizer, Pierre- Fabre, Roche, Sanofi and Teva. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.